SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing strong efficacy and potential disease-modifying effects. This, combined with a robust financial position and an eagerly awaited Investor Day, is fueling community discussion around significant undervaluation, a potential short squeeze, and best-in-class potential for its nanobody platform.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ trends as the market grapples with the fallout from the Supreme Court's tariff ruling and the subsequent 15% global tariffs, fueling community debate on economic uncertainty and the tech index's consistent resilience ahead of Nvidia's pivotal earnings.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for Bysanti, a new treatment for bipolar I disorder and schizophrenia, which was granted New Chemical Entity (NCE) status with patent protection extending to 2044. The community is actively discussing this as a major re-rating catalyst, anticipating significant institutional buying, and speculating on the drug's blockbuster potential alongside future pipeline developments.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

The recent acquisition of Astria Therapeutics, integrating the late-stage HAE drug navenibart, is driving BioCryst's conversation, especially with new data presentations for navenibart and Orladeyo expected at a medical conference and upcoming earnings. The community is actively discussing the potential of these pipeline advancements against persistent concerns about the stock's valuation and significant short interest.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending with strong community enthusiasm surrounding its anticipated BLA resubmission for deramiocel by the end of February, driving speculation for accelerated FDA approval and potential buyout interest, all while institutional ownership continues to increase.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending after receiving a prestigious Lightwave Award for its Teralight 1.6T product, intensifying community speculation for imminent major customer orders or partnerships in AI data center optical interconnects, even as some investors express frustration over management's continued silence and past capital raises.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending due to a dual financing announcement, including a non-dilutive royalty deal for its prostate cancer candidate and a concurrent public offering, which has sparked intense community debate over dilution and management's long-term commercialization strategy. Bulls view the capital raise as crucial validation and runway for its promising oncology pipeline, while bears express strong concerns about shareholder value and the impact on a potential "go it alone" approach.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community hotly debates the immense potential of its advanced GaN and SiC power platforms for next-gen AI data centers, particularly its role in NVIDIA's AI ecosystem. Despite the recognized breakthrough technology addressing critical efficiency needs, investors are expressing significant concern over the current absence of definitive, revenue-generating contracts, especially ahead of its upcoming earnings report.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Ryan Cohen's recent cryptic social media posts are driving intense speculation among investors about an imminent, monumental acquisition or strategic move, leveraging GameStop's substantial cash reserves. This dynamic fuels a fierce debate between ardent holders anticipating a massive short squeeze and skeptics citing ongoing price suppression and the absence of concrete company details.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to reports of record-breaking battery swap numbers during the Chinese New Year holiday, fueling bullish sentiment around its BaaS model and potential for profitability, further supported by D.E. Shaw significantly increasing its institutional stake. The community actively debates the long-term sustainability of these swap figures and the stock's persistent battle around the $5 mark, amidst ongoing discussions of market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vuzix (NASDAQ:VUZI) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded Vuzix from a "sell" rating to a "hold" rating in a report on Sunday...

Vuzix Launches All-in-One Enterprise Solutions Kits Featuring Native Microsoft Teams and Zoom for Hands-Free Remote Assistance

Vuzix Launches All-in-One Enterprise Solutions Kits Featuring Native Microsoft Teams and Zoom for Hands-Free Remote Assistance Vuzix Launches All-in-One Enterprise Solutions Kits Featuring Native...

Vuzix (NASDAQ:VUZI) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Vuzix from a "hold" rating to a "sell" rating in a research report on Saturday...

Vuzix Highlights Defense and Security OEM Waveguide Capabilities at SHOT Show 2026 in Las Vegas

Vuzix Highlights Defense and Security OEM Waveguide Capabilities at SHOT Show 2026 in Las Vegas Vuzix Highlights Defense and Security OEM Waveguide Capabilities at SHOT Show 2026 in Las Vegas PR...

Vuzix (NASDAQ:VUZI) Shares Pass Above Fifty Day Moving Average - What's Next?

Vuzix (NASDAQ:VUZI) Shares Cross Above Fifty Day Moving Average - Should You Sell...

Vuzix Ultralite Pro Enterprise Platform Recognized as CES 2026 Innovation Awards Honoree

Vuzix Ultralite Pro Enterprise Platform Recognized as CES 2026 Innovation Awards Honoree Vuzix Ultralite Pro Enterprise Platform Recognized as CES 2026 Innovation Awards Honoree PR Newswire...

Avegant and Vuzix Announce New Lightweight Binocular AR Reference Design

Avegant and Vuzix Announce New Lightweight Binocular AR Reference Design Avegant and Vuzix Announce New Lightweight Binocular AR Reference Design PR Newswire ROCHESTER, N.Y., Jan. 6, 2026 Design...

Vuzix Showcases AI-Powered Smart Glasses and Waveguide Solutions with its Global Ecosystem Partners at CES 2026

Vuzix Showcases AI-Powered Smart Glasses and Waveguide Solutions with its Global Ecosystem Partners at CES 2026 Vuzix Showcases AI-Powered Smart Glasses and Waveguide Solutions with its Global...

Vuzix (NASDAQ:VUZI) Shares Cross Above Fifty Day Moving Average - What's Next?

Vuzix (NASDAQ:VUZI) Share Price Passes Above 50-Day Moving Average - What's Next...

Tech Giants to Test Consumer AI Interest at CES

Dan Ives, Global Head of Tech Research at Wedbush Securities, shares his top AI plays for 2026. At CES, the annual consumer technology conference happening in Las Vegas next week, the biggest names...

Vuzix Corp. is a supplier of Smart-Glasses and Augmented Reality technologies and products for the consumer and enterprise markets. Its products include personal display and wearable computing devices that offer users a portable viewing experience, provide solutions for mobility, wearable displays and augmented reality. The firm also holds 246 patents and patents pending and numerous IP licenses in the Video Eyewear field. It has offices in Rochester, NY, Oxford, UK, and Tokyo, Japan. The company was founded by Paul J. Travers in 1997 and is headquartered in West Henrietta, NY.

Current Price	$2.76
Prev Close	$2.83
Open	$2.82
Dividend Yield	0.00%
50-Day Moving Average	$3.00
Beta	2.25
Avg. Volume	1.58M
PE Ratio	-5.63

52-Week High	$4.29
52-Week Low	$1.47
Market Capitalization	$222.75M
EPS (Annual)	-$1.08
Price to Book	7.86
Revenue Per Employee	$75,717.84

VUZI
Vuzix Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VUZI News

VUZIVuzix Corporation